Cargando…

Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data

We aimed to examine the frequency of treatment delays as well as the reasons and appropriateness of such delays in early stage colon cancer patients receiving adjuvant capecitabine by comparing data from pharmacy dispensing versus medical records. Patients diagnosed with stage II or III colon cancer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amlani, Adam, Kumar, Aalok, Ruan, Jenny Y., Cheung, Winson Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4884630/ https://www.ncbi.nlm.nih.gov/pubmed/27228415 http://dx.doi.org/10.1002/cam4.745

Ejemplares similares

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Prognostic factors of adjuvant chemotherapy discontinuation among stage III colon cancer patients: A survey of medical oncologists and a systematic review and meta‐analysis
por: Boyne, Devon J., et al.
Publicado: (2020)

Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
por: Eggington, S, et al.
Publicado: (2006)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Association of a Shortened Duration of Adjuvant Chemotherapy With Overall Survival Among Individuals With Stage III Colon Cancer
por: Boyne, Devon J., et al.
Publicado: (2021)

Discussions about reproductive and sexual health among young adult survivors of cancer
por: Wang, Ying, et al.
Publicado: (2016)

Compliance and Effective Management of the Hand-Foot Syndrome in Colon Cancer Patients Receiving Capecitabine as Adjuvant Chemotherapy
por: Son, Hyun-Sook, et al.
Publicado: (2009)

Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: A prospective cohort study
por: Jongeneel, Gabrielle, et al.
Publicado: (2021)

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis
por: Boyne, Devon J., et al.
Publicado: (2019)

Adjuvant 5‐Fluorouracil/leucovorin, capecitabine, and oxaliplatin‐related regimens for stage II/III colon cancer patients 66 years or older
por: Jones, Emily, et al.
Publicado: (2022)

The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients
por: Hsieh, Mei‐Chin, et al.
Publicado: (2016)

Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
por: Malik, Yasir G., et al.
Publicado: (2020)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Improving survival of stage II‐III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy
por: Li, Yang, et al.
Publicado: (2020)

Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study
por: Osawa, Hiroshi, et al.
Publicado: (2015)

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy
por: Famoso, Justin M., et al.
Publicado: (2017)

Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX
por: Ramaswamy, Anant, et al.
Publicado: (2019)

Cost-effectiveness of 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer: preplanned cost-effectiveness analysis of the JFMC37-0801 study
por: Shibahara, Hidetoshi, et al.
Publicado: (2022)

Estimating adjuvant treatment effects in Stage II colon cancer: Comparing the synthesis of randomized clinical trial data to real‐world data
por: Jongeneel, Gabrielle, et al.
Publicado: (2019)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy
por: Cho, Jang Ho, et al.
Publicado: (2017)

Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial
por: Li, Ning, et al.
Publicado: (2021)

Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
por: Tomita, Naohiro, et al.
Publicado: (2019)

Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer
por: Wang, Yizhuo, et al.
Publicado: (2016)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
por: Singh, Preet Paul, et al.
Publicado: (2016)

The impact of patient compliance with adjuvant radiotherapy: a comprehensive cohort study
por: Badakhshi, Harun, et al.
Publicado: (2013)

Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
por: Suto, Takeshi, et al.
Publicado: (2017)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer
por: Holmes, Frankie Ann, et al.
Publicado: (2018)

Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
por: Mochizuki, I, et al.
Publicado: (2012)

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
por: Yoshida, M., et al.
Publicado: (2014)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
por: Aitini, Enrico, et al.
Publicado: (2012)

Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma
por: Oblak, Irena, et al.
Publicado: (2014)

The association of comorbidities with administration of adjuvant chemotherapy in stage III colon cancer patients: a systematic review and meta-analysis
por: Boakye, Daniel, et al.
Publicado: (2021)

Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: A phase II study
por: Mizumoto, Yuki, et al.
Publicado: (2020)

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population‐based series and a randomized phase III study on adjuvant chemotherapy
por: Boye, Kjetil, et al.
Publicado: (2016)

Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
por: Yu, Qiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ah9efi4kjgnns8f30rjcb5kus0